Here is a concise recap of the most consequential Wall Street analyst notes from the past week, organized company by company, with the central arguments and numerical changes that drove each recommendation.
Jefferies Financial Group Inc (NYSE:JEF) - Monday
What changed: Morgan Stanley lowered its recommendation on Jefferies to Equal-weight and set a $49 price target.
Analyst rationale: Morgan Stanley shifted its valuation approach away from earnings multiples toward a price-to-tangible-book framework because of what it describes as "idiosyncratic" legal issues and credit-related worries. The note reduced 1Q26 EPS by 20% to $0.81 and highlighted revenue weakness across advisory and fixed income, partially offset by stronger activity in equities.
Valuation context: The analyst argued that a 13% ROTCE is being valued at only a 1.3x multiple in the current market. Morgan Stanley outlined a Bull Case at $70 and a Bear Case that implies a 0.7x P/TBV valuation near $27.
Hims & Hers Health Inc (NYSE:HIMS) - Tuesday
What changed: Bank of America upgraded Hims & Hers from Underperform to Neutral and raised its price target from $12.50 to $23.
Analyst rationale: The upgrade was driven by Novo Nordisk dropping its Wegovy lawsuit, removing the principal litigation and associated credit risk that had been compressing HIMS s valuation. BofA now values the company with a 23x CY26E EV/EBITDA multiple to capture GLP-1 revenue contributions.
Outlook and caveats: Even after the upgrade, BofA remains materially below Street consensus on revenue and EBITDA for 2026 and 2027. The firm described the risk/reward at current levels as balanced, noting that the elimination of legal overhang clears the way for valuation to reflect GLP-1 contributions even if possible future multiple expansion from pharmaceutical partnerships could be offset by earnings downside.
NIO Inc (HK:9866) - Wednesday
What changed: Nomura upgraded NIO to Buy with a $6.60 price target.
Analyst rationale: Nomura moved to Buy as shipments began to more closely resemble what it calls a "healthy business cycle." The bank lowered the price target to $6.60 but still cited roughly a 34% upside at that level.
Forecast adjustments: The analysts raised gross margin and operating margin forecasts, projecting a path toward non-GAAP operating breakeven by fiscal 2026. At the same time, Nomura trimmed shipment estimates to reflect a "challenging environment," but maintained a 25% compound annual growth rate assumption. The firm noted a forward valuation near 0.7x P/S and indicated that its discounted cash flow analysis incorporates a 1.5% terminal growth rate.
CVS Health Corp (NYSE:CVS) - Thursday
What changed: Bernstein upgraded CVS to Outperform and set a $94 price target.
Analyst rationale: Bernstein cited a recent legislative clearing event and resolved FTC settlements as reducing uncertainty around pharmacy benefit manager reform, which in the bank s view clears the way for a more visible earnings recovery.
Financial view: The bank forecasted that Aetna s earnings could nearly double over a three-year period as Medicare Advantage margins normalize. While 2026 was described as a continued period of pressure due to lingering PBM headwinds, Bernstein projected a 9% EPS compound annual growth rate through 2029 and argued that a 12x earnings multiple would imply the market is undervaluing a turnaround moving from uncertainty toward operational discipline.
PagerDuty Inc (NYSE:PD) - Friday
What changed: William Blair downgraded PagerDuty to Market Perform.
Analyst rationale: The downgrade followed a weak fourth quarter in which annual recurring revenue increased by just $2 million sequentially and net retention declined to 98%. Management attributed the slowdown to "seat-based headwinds," but the analyst characterized the underlying issue as a point-solution being displaced by larger platform competitors.
Operating outlook: William Blair projects a flat fiscal 2027 outlook, which would undercut the roughly 4% growth the Street had been expecting. Although PagerDuty trades at a discount to many SaaS peers, the analyst saw no clear catalyst for a re-rating while the company executes a transition to usage-based pricing and contends with intensified competition. The note concluded that without a significant reversal in growth, the risk-reward remains neutral.
Bottom line
The week s analyst notes reflect a mixture of legal resolution, shifting valuation frameworks and the ongoing struggle for growth in competitive software and EV markets. Investors faced upgraded prospects where legal clarity or margin improvement was visible, while concerns over credit, legal exposure or slowing organic growth prompted downgrades.